ProstaScint Fusion Imaging for Prostate Cancer

Home Site Map Contact UsSearch

Product Information
PIE Site Directory
Fusion Imaging Interactive Training
Case Studies

under construction

Central Abdominal Uptake of Indium-111 Capromab Pendetide (ProstaScint) Predicts for Poor Prognosis in Patients with Prostate Cancer

Click here to view this recently published article...
Haseman, et al. Urology 70: 303-308, 2007

Click here for ProstaScint Prescribing Information

To learn more on how to improve your diagnostic
confidence¹ visit PFI Resource Center

Information about ProstaScint
Fusion Imaging (PFI) for
Prostate Cancer
Information about Prostate
Cancer and ProstaScint
Fusion Imaging (PFI)

1: Schettino CJ, Kamer EL, Noz ME, et al. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR. 2004; 183:519-524.

Patient management should not be based on ProstaScint� scan results without appropriate confirmatory studies since in the pivotal trials, there was a high rate of false positive and false negative image interpretations. ProstaScint images should be interpreted only by physicians who have had specific training in ProstaScint image interpretation. Medications for the treatment of hypersensitivity reactions should be available during administration of this agent.

P-0428-08